Cagrisema Novo Nordisk - Search News

Novo Nordisk shares drop

The Wall Street Journal on MSN · 2d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Investopedia on MSN · 3d

Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight loss drug CagriSema.The average weight loss among those taking the new drug was 15.

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

Novo Nordisk Skeptic Finally Upgrades Stock

Seeking Alpha on MSN · 8h

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.

Markets Insider · 6h

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Bloomberg L.P. · 9h

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

6h

Wall Street's Biggest Novo Nordisk Bear Just Flipped--Here's Why He Says It's Time to Buy

After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.

3d

Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results